Kiniksa Pharmaceuticals International (KNSA) Fundamentals 2026 — P/E 63.1x, Revenue Analysis | SniperIQ
Kiniksa Pharmaceuticals International (KNSA) is a GB-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of $4.6B, trading at $61.83 on the NASDAQ. This SniperIQ fundamentals page covers Kiniksa Pharmaceuticals International's valuation (P/E 63.1x, P/B 7.8x), profitability (net margin 9.7%), revenue ($678M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Kiniksa Pharmaceuticals International's market cap?
Kiniksa Pharmaceuticals International (KNSA) has a market capitalization of approximately $4.6B, trading at $61.83 on the NASDAQ. Market cap moves with the live share price.
What is Kiniksa Pharmaceuticals International's P/E ratio?
Kiniksa Pharmaceuticals International's trailing twelve-month P/E ratio is 63.1x, with a price-to-book (P/B) of 7.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Kiniksa Pharmaceuticals International?
Kiniksa Pharmaceuticals International runs a net profit margin of 9.7%, a gross margin of 54.6%, and an operating margin of 12.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Kiniksa Pharmaceuticals International generate?
Kiniksa Pharmaceuticals International reported revenue of $678M for fiscal year 2025, with net income of $59M and earnings per share (EPS) of 0.8. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Kiniksa Pharmaceuticals International pay a dividend?
Kiniksa Pharmaceuticals International does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Kiniksa Pharmaceuticals International financially healthy?
Kiniksa Pharmaceuticals International carries a debt-to-equity ratio of 0.01x and a current ratio of 3.79x, with a market beta of 0.07. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Kiniksa Pharmaceuticals International a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Kiniksa Pharmaceuticals International (KNSA) the key facts are: market cap $4.6B, P/E 63.1x, revenue $678M, 52-week range 26.27-67.53. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Kiniksa Pharmaceuticals International's full fundamentals live
Get Kiniksa Pharmaceuticals International's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.